FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial

FDA Places Clinical Hold On Foghorn Therapeutics' Early-Stage Blood Cancer Trial

Source: 
Benzinga
snippet: 

The FDA has instituted a clinical hold on Foghorn Therapeutics Inc's Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).